Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023

– Data support the potential impact of VIR-2218 and VIR-3434 in addressing both HBV and HDV and underscore the Company’s confidence in its approach to a functional cure for HBV – SAN... | June 7, 2023

Related Keywords

United States ,Auckland ,New Zealand ,Vienna ,Wien ,Austria ,Florian Lempp ,Snehav Gupta ,Fung Yuen ,Edward Gane ,Marka Schmidt ,Key Laboratory Of Liver Research ,Vir Biotechnology Inc ,Kaiser Permanente Center ,Head Of Research ,Nasdaq ,Alnylam Pharmaceuticals Inc ,University Of Auckland ,Health Research ,School Of Clinical Medicine ,University Of Hong Kong ,European Association ,Phil Pang ,Executive Vice President ,Chief Medical Officer ,Interim Head ,American Association ,Liver Diseases ,Oral Presentation ,Man Fung Yuen ,Queen Mary Hospital ,Clinical Medicine ,State Key Laboratory ,Liver Research ,Chief Hepatologist ,Transplant Physician ,Deputy Director ,New Zealand Liver Transplant Unit ,Auckland City ,Clinical Pharmacology ,Enhanced Stabilization Chemistry Plus ,Alnylam Pharmaceuticals ,Vir Biotechnology ,Nc Stock Exchange ,News ,Information ,Press Release ,Data ,Support ,The ,Potential ,Impact ,F ,End ,N ,Ddressing ,Moth ,Gbv ,Dv ,Underscore ,Confidence ,Its ,Approach ,O ,Unctional ,Cure ,Or ,Bv Vir Us92764n1028 ,